LRIG1 and cancer: To further test the robustness of this result, we analyzed a 770 gene “pan-cancer” panel together with 31 AOM-DSS-induced (23 FFPE and 8 frozen) and 25 Apcfl;Lrig1-CreERT2 (12 FFPE and 13 frozen) Oct1 wild-type samples.